Alanna S. Ocampo-Pelland, Ph.D.

Research Associate

Alanna joined Metrum in October 2016 after completing her Ph.D. in Biomedical Engineering at the University of Connecticut. Her dissertation work included model-based meta-analysis for developing a population pharmacokinetic model to compare the dispositions of Vitamin D2, D3 and their 25-hydroxylated metabolites in healthy and osteoporotic patients. Extension of this work included linking 25OHD exposure to changes in bone-markers and bone mineral density, following Vitamin D doses commonly given as background therapy in osteoporosis drug trials. She is currently pursuing a postdoctoral position at Metrum, researching optimal modeling methods for analyzing tumor-size data from basket trials for cancer therapies aimed at specific genetic markers across a wide range of histologies.

Recent publications by this scientist

Extension of multi-scale systems pharmacology model to evaluate effect of vitamin D3 pharmacokinetics on bone health

October 1, 2016

Ocampo-Pelland AS, Gastonguay MR, Riggs MM.  Presented at the 7th American Conference on Pharmacometrics (ACoP), Bellevue, WA; October 2016.

Download PDF

Dexmedetomidine pharmacology in neonates and infants after open heart surgery

May 1, 2016

Su F, Gastonguay MR, Nicolson SC, DiLiberto M, Ocampo-Pelland A, Zuppa AF. Anesth Analg. 2016 May;122(5):1556-66.

Download PDF

Model-based meta-analysis for development of a population-pharmacokinetic (PPK) model for Vitamin D3 and its 25OHD3 metabolite using both individual and arm-level data

April 26, 2016

Ocampo-Pelland AS, Gastonguay MR, French JF, Riggs MM.  J Pharmacokinet Pharmacodyn. 2016 Apr;43(2):191-206.

Download PDF